Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Long-Term Debt Repayments (2016 - 2018)

Cardiff Oncology (CRDF) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $1.0 million as the latest value for Q2 2018.

  • Quarterly Long-Term Debt Repayments rose 566.67% to $1.0 million in Q2 2018 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Mar 2019, up 66.67% year-over-year, with the annual reading at $1.2 million for FY2018, 91.67% up from the prior year.
  • Long-Term Debt Repayments hit $1.0 million in Q2 2018 for Cardiff Oncology, up from $156526.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $14.7 million in Q3 2017 to a low of -$14.4 million in Q4 2017.
  • Historically, Long-Term Debt Repayments has averaged $1.2 million across 3 years, with a median of $156526.0 in 2017.
  • Biggest five-year swings in Long-Term Debt Repayments: crashed 261.57% in 2017 and later surged 566.67% in 2018.
  • Year by year, Long-Term Debt Repayments stood at $8.9 million in 2016, then plummeted by 261.57% to -$14.4 million in 2017, then soared by 107.26% to $1.0 million in 2018.
  • Business Quant data shows Long-Term Debt Repayments for CRDF at $1.0 million in Q2 2018, $156526.0 in Q1 2018, and -$14.4 million in Q4 2017.